Back

Real-world use of rosuvastatin 40 mg and ezetimibe 10 mg after ACS: is this combination effective in achieving guideline-recommended LDL-C goals after discharge?

20 March 2026 (08:30 - 18:00)
Organised by: Logo
Congress Presentation Part of: Poster session (1) Secondary Prevention ACVC Premium Access ESC Acute CardioVascular Care 2026 Association for Acute CardioVascular Care (ACVC)

About the speaker

Photo
Doctor Marco Biasin

Alto Vicentino Hospital, Santorso (Italy)

71 More presentations in this session

Presentation thumbnail
Multimodality imaging of the aortic root and ascending aorta: a comparative study of CTA and echocardiography
Mr G. Imperatore (Pisa, IT)
Abstract Slides
Presentation thumbnail
Impact of atrial fibrillation burden on heart failure device alerts and therapy delivery: insights from remote monitoring in an island-based heart failure cohor
Doctor I. Almeida (Ponta Delgada, PT)
Abstract Slides
Presentation thumbnail
Respiratory infections as triggers of acute cardiovascular complications: a case series of new-onset atrial fibrillation and heart failure
Doctor A. Akhtar (Waterford, IE)
Abstract Slides
Presentation thumbnail
Stabilizing the unstable: characterization of advanced heart failure patients under intermittent levosimendan therapy
Doctor R. Brandao (Amadora, PT)
Abstract Slides
Presentation thumbnail
Predictors of Levosimendan reinitiation in patients with advanced heart failure undergoing intermittent inotropic therapy- is the lung that important?
Doctor R. Brandao (Amadora, PT)
Abstract Slides

Access the full session

Session thumbnail
Poster session (1)

The Event

Event poster

ESC Acute CardioVascular Care 2026

20 March 2026 08:30 CET
You may be interested in
thumbnail
Congress Presentation
STEMI and lipid management: are current prescriptions at discharge enough to meet target goals?
thumbnail
Congress Presentation
A global perspective on lipid control after acute coronary syndrome: are we doing enough?
thumbnail
Congress Presentation
Does early initiation of non-statin therapy, evolocumab with LDL-C <50mg/dL contribute to the reduction of hospital readmissions in patients with ACS?: a single center real world evidence from ELAINE

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources